Across TCGA pan-cancer cohorts, BCL2L15 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated BCL2L15 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BCL2L15 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BCL2L15 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, UCEC, and COAD are the cancer types where BCL2L15 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.719	0.428	<.001	97	view →
UCEC	OS	Tertile	All	1.000	0.803	.006	32	view →
COAD	DFS	Tertile	II,III,IV	1.000	0.915	.042	12	view →
LSCC	DFS	Quartile	All	0.839	0.367	.022	5	view →
LUAD	DFS	Quartile	All	0.821	0.980	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: BCL2L15 tumor-vs-normal RNA expression · all BCL2L15 data types